Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PolipillV1 is a fixed-dose combination pharmaceutical drug designed to improve treatment compliance in patients at high cardiovascular risk or with established cardiovascular disease. It combines four well-known medications: aspirin (75mg), simvastatin (40mg), lisinopril (10mg), and atenolol (50mg). Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase enzymes, primarily COX-1, to reduce thromboxane A2 production. Simvastatin is a statin that lowers cholesterol by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. Lisinopril is an ACE inhibitor, reducing blood pressure by blocking the conversion of angiotensin I to angiotensin II. Atenolol is a selective beta-1 adrenergic receptor antagonist, which decreases heart rate and cardiac output, thereby lowering blood pressure. This combination aims to provide comprehensive cardiovascular protection by addressing multiple risk factors simultaneously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PolipillV1.